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Background 
Conclusion 
Allergic rhinoconjunctivitis (ARC) constitutes a large burden for 
society. The disease prevalence is increasing and approximately 20-
25% of the European population suffers from respiratory allergies 
including ARC. The majority of patients are treated with symptomatic 
pharmacotherapy; however a large proportion remain uncontrolled 
despite the use of such treatments. Specific immunotherapy (SIT) is 
the only treatment documented to target the underlying allergic 
disease and activate immunomodulatory mechanisms leading to a 
sustained effect after completion of treatment. Based on a Danish 
societal and health care perspective, this analysis shows the 
economic consequences if adult patients with grass pollen induced 
ARC uncontrolled on symptomatic medications are treated with a 
grass allergy immunotherapy tablet (AIT) instead of the currently 
established clinical practice of subcutaneous immunotherapy (SCIT).  
Results 
Treating ARC patients with grass AIT instead of SCIT is cost-saving 
due to a significantly reduced number of physician visits needed, 
leading to a reduction in direct treatment costs, direct patient costs 
and indirect costs (Table 2 and Figure 2). 
Method 
A cost-minimisation analysis (CMA) was performed comparing 
the SQ-standardised grass AIT (Grazax, Phleum pratense, 
75,000 SQ-T/2,800 BAU, ALK, Denmark) with SCIT (Alutard, 
Phleum pratense, 100,000 SQ-U, ALK, Denmark) (Figure 1). The 
choice of CMA was based on a review publication and a meta-
analysis, which concluded that the clinical effect of AIT is similar 
in magnitude to that observed for SCIT in grass pollen induced 
ARC patients with similar disease severity. Health care utilisation 
was measured in physical units based on national guidelines, 
literature reviews and expert opinion. The valuation in unit costs 
was based on drug tariffs, physician fee structures and wage 
statistics in 2010. Key model assumptions can be found in  
Table 1. 
In patients with grass pollen induced ARC, this 
cost-minimisation analysis shows that treatment 
with the SQ-standardised grass AIT reduces 
both direct and in-direct treatment costs 
compared with SCIT. Thus, the SQ-standardised 
grass AIT is a cost-saving alternative to SCIT 
both from a societal and health care perspective 
Figure 1: Treatment sequences for the two products compared in the CMA 
Table 1: Key model assumptions used for the CMA 
Cost category Grass AIT SCIT Cost reduction  
(Grass AIT-SCIT) 
Medication 3043 1266 1777 
Physician visits 312 3394 -3082 
Direct treatment costs 3355 4660 -1306 
Direct patient costs (travel expense) 33 171 -138 
Direct treatment costs + patient costs 3388 4831 -1443 
Indirect costs (patient productivity) 506 2589 -2083 
Total costs 3894 7420 -3526 
Table 2: Costs (in €) in relation to treatment with Grass AIT and SCIT 
A sensitivity analysis confirmed the robustness of the results in 
Table 2 and Figure 2. 
Figure 2: Direct treatment and patient costs, indirect costs and total costs (in €) in 
relation to treatment with Grass AIT and SCIT 
Model assumptions Grass AIT SCIT 
Treatment length Patients are treated for 3 years according to 
current treatment guidelines 
Difference in treatment length (3 or 5 years): 80% 
are treated for 3 years; 20% of patients are treated 
for 5 years  
Treatment/ 
consultations 
Year 1: Treatment initiated by two 
consultations:  
 
a) administration of first treatment dose  
b) Investigation of desired treatment effect 
approx. 1 month later.  
 
Initial consultations are followed by an 
additional check-up consultation  
 
Year 2 and 3: 2 check-up consultations 
every year 
 
All check-up consultations take place at a 
GPs office 
Updosing phase: Weekly injections in a period of 15 
weeks 
 
Transition phase: 1 injection after 2 weeks; a second 
injection 4 weeks later 
 
Maintenance phase: Approx. 8 weeks between 
injections 
 
Vials are personal and cannot be shared between 
patients 
Compliance Compliance: 80% Compliance (updosing phase): 100% Compliance 
(remaining treatment period): 90% 
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